Arca
Skip to content
Tools
Tools

SRC: Proto-oncogene tyrosine-protein kinase Src

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors.

  • Drugs that act on it: 8
  • Approved: 3
  • In phases 1 to 3: 5
  • Sponsors: 5

Who Is On It, and How Far Along

Every drug ChEMBL records acting on SRC, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved3

  • Bosutinib
  • Tirbanibulin
  • Vandetanib

Phase 31

  • Saracatinib

Phase 21

  • AZM-475271

Phase 13

  • AZD-0424
  • JNJ-26483327
  • PD-0166285

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

Modalities

Drugs on this target by ChEMBL molecule type.

  • Small molecule8100%

The Landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Tyrosine-protein kinase SRC inhibitor.
BosutinibApprovedPfizerSmall moleculeInhibitor—12—
TirbanibulinApprovedAlmirallSmall moleculeInhibitor—6—
VandetanibApprovedSanofiSmall moleculeInhibitor—3Boxed warning
SaracatinibPhase 3AstraZeneca PharmaceuticalsSmall moleculeInhibitor—2—
AZM-475271Phase 2—Small moleculeInhibitor—0—
AZD-0424Phase 1—Small moleculeInhibitor—0—
JNJ-26483327Phase 1Johnson & JohnsonSmall moleculeInhibitor—0—
PD-0166285Phase 1—Small moleculeInhibitor—0—

Open Trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 19 in all, from ClinicalTrials.gov.
A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIsBosutinibPhase 3Not yet recruitingEnliven Therapeutics2026-10-29
Outcomes Associated With Tirbanibulin for Large Field Application on the Face in the U.S (CLEAR)Tirbanibulin—RecruitingAvant Health LLC2026-06-18
A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in GermanyBosutinib—RecruitingNovartis Pharmaceuticals2026-04-24
Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and ForeheadTirbanibulinPhase 3Not yet recruitingUniversity Hospital, Lille2025-12-09
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) TherapyBosutinib—RecruitingNovartis Pharmaceuticals2025-07-29
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin OintmentTirbanibulinPhase 1 / Phase 2RecruitingBruce Robinson, MD2025-06-08
Investigation of the Efficacy and Tolerability of Topical Applied Tirbanibulin on Actinic Keratoses With Downward-directed Proliferation PatternsTirbanibulin—RecruitingThomas Dirschka2024-10-18
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerVandetanibPhase 2RecruitingWest China Hospital2024-07-01
Study of Olverembatinib (HQP1351) in Patients With CML-CPBosutinibPhase 3RecruitingAscentage Pharma Group Inc.2024-05-21
A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).Bosutinib—RecruitingPfizer2024-03-07
Tirbanubulin (Klisiry®) in the Treatment of Basal Cell CarcinomaTirbanibulinPhase 2RecruitingCentre Hospitalier Universitaire de Nice2023-11-01
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or ScalpTirbanibulinPhase 4Active, not recruitingAlmirall, S.A.2022-05-24
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPBosutinibPhase 3Active, not recruitingNovartis Pharmaceuticals2021-07-21
Asciminib Roll-over StudyBosutinibPhase 4RecruitingNovartis Pharmaceuticals2021-05-07
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World PopulationBosutinibPhase 2Active, not recruitingBaylor College of Medicine2020-11-12
Saracatinib in the Treatment of Idiopathic Pulmonary FibrosisSaracatinibPhase 1 / Phase 2Active, not recruitingNational Jewish Health2020-10-22
Saracatinib Trial TO Prevent FOPSaracatinibPhase 2Active, not recruitingAmsterdam UMC, location VUmc2020-03-13
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid CancerVandetanibPhase 3Active, not recruitingLoxo Oncology, Inc.2019-12-26
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerVandetanibPhase 2Active, not recruitingUNICANCER2014-11-24

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Cancer
0.63
Medullary thyroid gland carcinoma
0.55
Noonan syndrome
0.54
Neoplasm
0.54
Costello syndrome
0.51
Rare hemorrhagic disorder due to a constitutional platelet anomaly
0.51
Non-small cell lung carcinoma
0.46
Listeriosis
0.46

Genes and Related Targets

Complexes and families that share a gene with this target
Genes
SRC
Related
SRC

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL267, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P12931, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.